Narrative Review Reimagines **Heart-Kidney-Metabolic Health**, Emphasizing **SGLT-2 Inhibitors**, **GLP-1 Receptor Agonists**, and Emerging Therapies
Background
The interconnectedness of cardiovascular, renal, and metabolic diseases presents a significant challenge in modern healthcare, often leading to suboptimal outcomes when treated in isolation. Traditional therapeutic approaches frequently fail to address the systemic nature of these conditions, leaving a critical gap for holistic, integrated care strategies. This review aims to contextualize the contemporary role of established agents like SGLT-2 inhibitors and GLP-1 receptor agonists while exploring novel mechanisms and compounds that offer potential for comprehensive management across the cardiorenal-metabolic continuum.
Study Design
This manuscript was developed as a narrative review to synthesize and critically contextualize the contemporary role of SGLT-2 inhibitors and GLP-1 receptor agonists in cardiovascular prevention within the broader cardiorenal–metabolic continuum. The objective was not to perform a formal quantitative meta-analysis or systematic review, but rather to provide a comprehensive overview and critical discussion of current and future perspectives in managing these interconnected health challenges.
Results
The review highlighted the established benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in improving cardiovascular outcomes and managing type 2 diabetes. It explored emerging treatments such as glimins and glucokinase activators (GKAs), which offer novel strategies for enhancing insulin secretion and reducing glucose production. Future perspectives in diabetes management included the potential of retatrutide as a triple agonist. Furthermore, systemic interventions such as oral collagen peptides, coenzyme Q10, ceramides, and antioxidants like astaxanthin and resveratrol were discussed. > These agents may reduce systemic oxidative stress, modulate NF-κB activation, and improve mitochondrial function in cutaneous cells, suggesting broader systemic benefits beyond glucose control.
Key Findings
- SGLT-2 inhibitors and GLP-1 receptor agonists are crucial for cardiovascular prevention in cardiorenal-metabolic health.
- Emerging treatments like glimins and glucokinase activators enhance
insulin secretionand reduceglucose production. - Retatrutide is highlighted as a promising future triple agonist for advanced diabetes management.
- Systemic interventions like oral collagen peptides and antioxidants may reduce
oxidative stressand improvemitochondrial function. - A holistic, integrated approach is crucial for optimizing heart-kidney-metabolic health.
Why It Matters
This review underscores the critical need for a holistic approach to managing cardiorenal-metabolic health, moving beyond siloed treatment strategies. For clinicians and biohackers, it reinforces the established benefits of SGLT-2 inhibitors and GLP-1 receptor agonists while pointing to future directions with agents like retatrutide and systemic interventions. Understanding the interconnectedness of these systems can inform more comprehensive protocols, potentially combining pharmaceutical interventions with nutraceuticals to target multiple pathways like oxidative stress and NF-κB activation. This perspective encourages a broader view of patient care, integrating diverse therapeutic modalities for improved long-term outcomes.
cardiorenal-metabolic
glp-1-agonist
sglt-2-inhibitor
retatrutide
collagen-peptides
antioxidants